Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cautious Report Unlikely To Slow Partial-Breast Irradiation Market, Firms Say

This article was originally published in The Gray Sheet

Executive Summary

In its most recent assessment of accelerated partial-breast irradiation (APBI), the BlueCross BlueShield Association Technology Evaluation Center reiterated that APBI as the sole radiation treatment following breast-conserving surgery for early stage cancer has not been proven beneficial. But companies in the budding APBI market say the report does not deter them from marketing or developing their treatments (see chart: "1FDA-Cleared APBI Devices ")
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel